Dr. Sutherland has over 25 years of working experience in biotech with expertise in target validation, lead identification, and building a preclinical package to support IND. She has championed and lead the preclinical efforts from target discovery to clinical testing for several antibody-drug conjugates and coordinated the screening and testing of other lead candidates at Seattle Genetics. Previously she was a member of the Target Validation team at Celltech R&D that led to the selection and development of romosozumab (Evenity™).